New therapeutic target expands options for multiple myeloma

In a signifier 1 objective trial, attraction with the investigational bispecific antibody cevostamab reduced crab successful much than 40% of patients with aggregate myeloma, galore of whom had already undergone aggregate different crab treatments, and produced a median duration of effect of 11.2 months earlier the crab progressed.